Cambridge Healthtech Institute's Inaugural
Advancing CNS Biotherapeutics and Crossing the Blood-Brain Barrier
( 血脑障壁 )
Innovation, New Targets, Tools, Delivery and New Research Updates
2018年1月8日 - 9日
Cambridge Healthtech Institute's Inaugural Advancing CNS Biotherapeutics and Crossing the Blood-Brain Barrier conference strives to bring you the hottest topics and biggest opportunities in discovering and developing highly efficacious therapeutic agents against CNS disorders and innovative strategies for delivering therapies across the blood-brain barrier (BBB). This new meeting will brainstorm ideas and share new research on topics such as the biologics for CNS targets and biomarkers, brain cancer, neurodegeneration, neuroinflammation, neuroimmunology, alteration of CNS/BBB barriers due to injury or disease, preclinical models, neuroimaging, tools for prediction of brain penetration, and updates from the industry on topics such as antibody delivery and vector-mediated transport across BBB.
This conference will feature stimulating discussions and a friendly place to network with peers. We invite you to present a poster, or to attend to learn from and network with the leading experts from around the globe.
CONSIDERATIONS FOR DISCOVERY AND DEVELOPMENT FOR CNS and BBB THERAPIES
Efficient and Safe Biologics for Diseases of CNS
Per-Ola Freskgard, Ph.D., Vice Director and Senior Leader, Neuroscience, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.
But HOW Did It Affect the Brain
Lois A. Lampson, Ph.D., Associate Professor of Neurosurgery, Brigham & Women's Hospital/Harvard Medical School
DRUG DELIVERY AND MOLECULAR TRANSPORT ACROSS BBB: UPDATES FROM INDUSTRY
Deliverable Biologics at the Blood-Brain Barrier
Torben Moos, M.D., Ph.D., DMSc., Professor, Medicine and Health Technology, Aalborg University
Delivery across the BBB, Utilizing Single-Domain Antibodies and a New Receptor-Mediated Transcytosis Pathway
Kristin Kemmerich, Ph.D., Head, Antibody Generation Section at National Research Council Canada
Brain Penetrating IgG Fusion Proteins: From Genetic Engineering to Clinical Trials in Lysosomal Storage Disorders
Ruben Boado, Ph.D., Vice President, Research & Development/Co-Founder, ArmaGen, Inc.
IMAGING, PRECLINICAL TOOLS, MODELS AND TRANSLATIONS STRATEGIES
Extremely Fast Clinical MRI for Predicting and Real-Time Monitoring of Intra-Arterial Opening of the Blood Brain Barrier
Miroslaw Janowski, M.D., Ph.D., Associate Professor, Radiology, Johns Hopkins University
Development of Highly Efficient BBB Transport of Antibodies to the CNS Using in vivo Phage Display with Single Domain VNAR to the Transferrin Receptor
Frank S. Walsh, Ph.D., CEO, Ossianix